Navigation Links
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Date:4/10/2008

he standard treatment of GBM makes this a promising study," said BiPar Executive Vice President Barry Sherman, M.D. "It is the promise of this approach that encouraged the leaders of NABTT to evaluate BSI-201 in patients with GBM."

GBM is an aggressive form of brain cancer that strikes 10,000 patients a year in the United States. Currently, patients are often treated with radiotherapy and chemotherapy where the median survival is under 15 months. The initial study phase will evaluate the safety and tolerability of BSI-201 in combination with temozolomide given at standard doses. The Phase 2 component will assess BSI-201 combined with temozolomide plus radiation therapy in newly diagnosed GBM patients, where the primary endpoint is overall survival.

Additional Data to be Presented at Upcoming AACR 2008 Meeting

BiPar will present preclinical data on BSI-201 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Monday, April 14, 2008. The abstract, "Activity of BSI-201, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, alone and in combination with topotecan in human ovarian xenografts," will be presented at 8 a.m. in the "New Agents and Therapeutic Approaches" session.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on novel mechanisms of action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead PARP inhibitor program in Phase 2 clinical trials in multiple solid tumor settings.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re/--TheFDAgrantedtraditionalapprovalforINTELENCE&...nscriptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTI...adultswhoareexperiencingvirologicfailurewithHIV-1s...)agents.Thetraditionalapprovalisbasedon48-weekdata...CEiscurrentlymarketedintheU.S.byTibotecTherapeutic...
(Date:11/25/2009)...ire/--RegadoBiosciences,aprivatelyheldcompanyleadi...controlagents,announcedthatDavidMazzo,PhD,CEOandPr...lHealthCareConferenceattheNewYorkPalaceHotelinNewY...EST)onTuesday,December1andwillincludeanoverviewoft...tprogram,theanticoagulantsystem,REG1.Thehealthcare...
(Date:11/25/2009)...re-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ),amedical...ysissystems,announcedtodaythatClintSeverson,chairm...ualPiperJaffrayHealthCareConferenceonWednesday,Dec...heNewYorkPalaceHotelinNewYorkCity. ,, AboutAba...rtablebloodanalysissystemsforuseinanyveterinaryorh...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Identafi 28TM 29 3000 Picked by Dentistry Today Magazine as One of the Top 100 Products of 2009 50599 1Identafi 28TM 29 3000 Picked by Dentistry Today Magazine as One of the Top 100 Products of 2009 50599 2Jury Convicts Los Angeles Physician Assistant for Stealing Doctors Identity and Defrauding Medicare in 247 7 Million Scheme 50595 1Jury Convicts Los Angeles Physician Assistant for Stealing Doctors Identity and Defrauding Medicare in 247 7 Million Scheme 50595 2Jury Convicts Los Angeles Physician Assistant for Stealing Doctors Identity and Defrauding Medicare in 247 7 Million Scheme 50595 3Jury Convicts Los Angeles Physician Assistant for Stealing Doctors Identity and Defrauding Medicare in 247 7 Million Scheme 50595 4Growth Hormone May Build Muscle in Older Men 50591 1Growth Hormone May Build Muscle in Older Men 50591 2
...arch 11 InteKrin Therapeutics, Inc., a clinical s..., metabolism and obesity, today announced it has c...y of INT131, a novel, non-TZD selective modulator ... diabetes (T2DM). INT131-007 is a 24 week, high d...controlled study of INT131 at four doses in poorly...
...h 10 BioSpecifics Technologies Corp. (Nasdaq: B...t in class collagenase-based products, today annou...l present a corporate overview at the upcoming Cow...on Tuesday, March 17, 2009, at 9:30am ET at the Bo...ebcast of the presentation can be accessed at www...
Other Medicine Technology:InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study 2
(Date:11/25/2009)...Nov.25/PRNewswire/--TheBartleHallConventionCenterw...conDec.9-10,whenKansasCityhoststhelatestinaserieso...freecliniceventhasthepotentialtobethebiggestoneyet...beheldonweekdaysinsteadofoveraweekend,"SheriWood,e...presidentoftheNationalAssociationofFreeClinics(NAF...
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...d evidence of a statistically significant survival...ose estrogen receptor (ER)-positive tumors had hig...-118 (ER-alpha S118-P), according to a brief commu...nal of the National Cancer Institute . , Approxi...amoxifen. Preclinical studies have shown that ER-a...
(Date:11/25/2009)... Evaluation and treatment clinics to resume Mond...Vocus) November 25, 2009 -- Centegra Health System...N1 vaccine shots at four Centegra Primary Care (CP...accine has arrived. The clinics are at CPC sites i... will be open as follows: ,   From 4:3...
(Date:11/25/2009)...ov.25/PRNewswire-USNewswire/--TheAmericanAssociati...Actof2009,"S.2128,whichisdesignedtosubstantiallyim...icare.ThebillwasintroducedbySen.GeorgeLeMieux(R-Fl...theAmericanAssociationforHomecareoutlinedinits13-p...edtoCongressinFebruary.Thoseprovisionsincludecalli...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...ne 2008: New data presented today at EULAR 2008, ... Rheumatism in Paris, France, show that over half ...otrexate monotherapy improved when either abatacep...infliximab versus placebo, a Trial for Tolerabilit...
...ind, bioengineers and bioscientists at Rice Univer...ds, have shown they can grow denser bone tissue by...e porous material used to pattern the bone. , The.... The new discipline combines the latest research ...
...ion Orthopedics, Inc., a,leader in orthopedic extr...opedic executives, William F. Warrender, Jr., John...Presidents. Their extensive background and,experie...Global Sales. He brings more than 25 years of sale...
...and have had a piercing somewhere other than their...ns, and one in 100 piercings resulting in a hospit...mj.com today. , The study, carried out by public...ikely than men to have a body piercing and the mos...
...surprise not only for tomato lovers around the cou...ped bacterium that causes misery for millions of p...ne journal PloS One , researchers say they,ve ide...protein that allows the bacteria to maintain a low...
...RNewswire/-- Express Scripts has entered,into a bi...Division of MSC,-- Medical Services Company. MSC, ...- pharmacy and ancillary -- will retain the MSC br... PBM,companies in North America, providing PBM ser...
Other Medicine News:Health News:Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients 2Health News:Nanoparticles aid bone growth 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:1 in 10 adults has a non-earlobe piercing 2Health News:Salmonella: Trickier than we imagined 2Health News:Salmonella: Trickier than we imagined 3Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 2Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 3
Neumann Tying Forceps - Straight
Neumann Tying Forceps - Angled
Shepard Straight Tying Forceps
Shepard Curved Tying Forceps
Medicine Products: